Xolair (omalizumab), an approved therapy for allergic asthma and chronic spontaneous urticaria (CSU), shows promise for treating idiopathic angioedema, according to data from a small Phase 4 trial. In the study, treatment for roughly six months with Xolair as an add-on therapy lessened disease activity when compared to…
One person out of six treated with Ruconest (rhC1INH) for idiopathic non-histaminergic angioedema (InH-AAE) as part of an exploratory study showed a positive clinical response to the medication. The findings may mean that Ruconest is effective in a subset of InH-AAE patients, the researchers noted. The study, “…
I triumphantly pressed enter and marveled at my epic post on social media. There were no hospital visits, no rushes to the emergency room, and no urgent phone calls to after-hour physicians’ lines. Our second-born, affectionally known as Ladybug, had gone three solid weeks without any medical incidents. What better…
I haplessly fell backward on my bed, blew a sharp breath out of my mouth, and stared at the ceiling. We had made it to the middle of the week without any incidents with my oldest daughter, nicknamed Ladybug. We hadn’t needed to make a trip to see the pediatrician,…
Angioedema seems to predict poorer responses and lower chances of remission in chronic urticaria patients receiving Xolair (omalizumab), a retrospective study shows. The study, “Angioedema is an unfavorable factor for the response to omalizumab in chronic spontaneous urticaria: a retrospective study,” was published in the journal…
Get regular updates to your inbox.
